On September 2, Moderna, Inc. fell 3.81% in regular trading, trading at $147.84/share, with turnover of $813 million. The decline was driven by lingering mechanical selling pressure from the company's recent convertible debt issuance, compounded by negative sentiment across the biotech sector.
On the financing side, Moderna recently completed the pricing of $2.6 billion in zero-coupon convertible senior notes due 2032, with the offering size upsized from the originally planned $2 billion. Arbitrage funds that purchased the convertible notes typically short the underlying stock as a hedge, generating sustained mechanical selling pressure that has not yet been fully absorbed. The notes carry an initial conversion price at a 47.5% premium to the stock's closing price on August 27, with capped call transactions setting an upper bound at a 175% premium.
Simultaneously, peer BioNTech recently announced the termination of its colorectal cancer vaccine Phase 2 clinical trial, weighing on overall biopharma sector sentiment. Although at least five institutions — including Argus Research, Barclays, and JPMorgan — have recently upgraded Moderna's rating or raised target prices following its melanoma cancer vaccine Phase 3 success, the broader Wall Street consensus remains at Hold, reflecting unresolved uncertainty around cancer vaccine commercialization prospects.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments